➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Boehringer Ingelheim

Last Updated: January 26, 2021

DrugPatentWatch Database Preview

Patent: 7,608,261

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,608,261
Title:VEGF antagonist formulations suitable for intravitreal administration
Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence shown in SEQ ID NO:4.
Inventor(s): Furfine; Eric (Concord, MA), Dix; Daniel (LaGrangeville, NY), Graham; Kenneth S. (Pleasant Valley, NY), Frye; Kelly (Pomona, NY)
Assignee: Regeneron Pharmacuticals, Inc. (Tarrytown, NY)
Application Number:11/818,463
Patent Claims:see list of patent claims

Details for Patent 7,608,261

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Regeneron Pharmaceuticals EYLEA aflibercept INJECTABLE; INJECTION 125387 001 2011-11-18   Start Trial Regeneron Pharmacuticals, Inc. (Tarrytown, NY) 2039-03-29 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 7,608,261

Country Patent Number Estimated Expiration
South Africa 200809827   Start Trial
World Intellectual Property Organization (WIPO) 2007149334   Start Trial
United States of America 10400025   Start Trial
United States of America 10464992   Start Trial
United States of America 2007293432   Start Trial
United States of America 2010075903   Start Trial
United States of America 2011257601   Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.